Management ChangeJun 30, 2026, 04:37 PM
Imunon Appoints Josh Blacher as Interim CFO; Jeffrey Church Retires
AI Summary
Imunon, Inc. announced the retirement of its interim Chief Financial Officer, Jeffrey Church, effective July 1, 2026. Mr. Church will transition to a consulting role to ensure a smooth handover. Concurrently, the company appointed Josh Blacher as the new interim Chief Financial Officer, also effective July 1, 2026. Mr. Blacher, an employee of Danforth Health, Inc., will serve as both principal financial and accounting officer.
Key Highlights
- Jeffrey Church retired as interim Chief Financial Officer, effective July 1, 2026.
- Mr. Church will continue in a consulting role, receiving a monthly retainer of $10,000.
- Josh Blacher was appointed as the new interim Chief Financial Officer, effective July 1, 2026.
- Mr. Blacher will also serve as the Company's principal financial and accounting officer.
- Mr. Blacher is an employee of Danforth Health, Inc., a financial advisory services firm.
- Imunon will pay Danforth Health, Inc. $475 per hour for Mr. Blacher's services.
- Mr. Blacher has prior CFO experience at BullFrog AI, Inmed Pharmaceuticals, Therapix Biosciences, and Galmed Pharmaceuticals.
- Mr. Church's departure is due to retirement and without any disagreements with management.
Price Impact
More from IMNN